JMP Securities Reaffirms Market Outperform Rating for Sutro Biopharma (NASDAQ:STRO)

JMP Securities reiterated their market outperform rating on shares of Sutro Biopharma (NASDAQ:STRO – Free Report) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $17.00 price objective on the stock. STRO has been the topic of several other research reports. Truist Financial reduced their price target on […]

Leave a Reply

Your email address will not be published.

Previous post Taitron Components (NASDAQ:TAIT) Earns Hold Rating from Analysts at StockNews.com
Next post Reviewing MVB Financial (NASDAQ:MVBF) and Sberbank of Russia (OTCMKTS:SBRCY)